Statistics

Total Visits

Views
Non-randomized, open label phase II trial evaluating the safety and efficacy of taxotere (T) followed by myocet (M) + cyclophosphamide (C) as first-line treatment for HER2-negative breast cancer (BC)17

Select a period of time:

Number of views in the range

Views
Non-randomized, open label phase II trial evaluating the safety and efficacy of taxotere (T) followed by myocet (M) + cyclophosphamide (C) as first-line treatment for HER2-negative breast cancer (BC)8

Views

Views
May 20245
June 20240
July 20240
August 20241
September 20240
October 20240
November 20242
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States6
Belgium1
Spain1
 

Top cities views

Views
Chicago4
Santiago de Compostela1